🏛️ Company factsSEC filings + FINRA official data
Annual revenue $61.2B · latest quarter up 10.2% YoY · profitable (FY net income $1.8B) · short activity within its normal range.
FY revenue
$61.2B
2025-12
Latest Q YoY
+10.2%
Gross margin
19.7%
FY net income
$1.8B
Diluted EPS
$1.02
Short volume
54.2%
20d avg 54.5% · normal
🐋 5%+ ownership filings (last 180d)
The parties below hold over 5% of this company and disclosed it to the SEC (mandatory in US markets). "Activist" filers state an intent to influence the company; "Passive" are pure investment positions.
- 2026-04-29passive (13G)VANGUARD CAPITAL MANAGEMENT LLC
- 2026-03-26passive (13G)VANGUARD GROUP INC
🎯 Market expectations
Expectation reliability High · 74/100Nasdaq analyst consensus · the pre-news baseline
- Jun 2026$3.65 vs $3.64+0.27%
- Mar 2026$2.65 vs $2.62+1.15%
- Dec 2025$2.71 vs $2.66+1.88%
- Sep 2025$1.86 vs $1.77+5.08%
The takeaway
It has tracked consensus closely — no systematic over- or under-shooting.
Analyst estimates, not our forecast · not investment advice
What's moving this stock lately
1 direct · 0 2nd-order · 0 thematicRanked by impact strength · strength = estimated move × freshness decay (shorter-lived effects decay faster)
Cited as a high-yield pharma name; sentiment-only attention with no fundamental new information
Also named: O · MO · VZ · XOM
🕰️ Price × news · engine report card
Drag to pan, scroll to zoom · real daily bars and volume
📜 Call history (newest first
8 engine calls on this stock — each with direction, magnitude and its verified outcome · sign up to view
Sign up · free 7-day trial →Impact chains · crowding · conviction engine · insider signals — free 7-day trial on signup.
Sign up · free 7-day trial →